DNX and XL-protein Announce Collaboration
News Jul 02, 2015
DNX Biopharmaceuticals, Inc. and XL-protein GmbH have announced a collaboration for the development and commercialization of novel, long-acting biopharmaceutical products. Under this strategic collaboration, XLp will contribute its half-life extension platform technology (PASylation®) and certain molecules that have completed in vivo efficacy proof-of-concept and preclinical studies, and DNX will add its pipeline of candidate molecules for development and commercialization to address a range of unmet needs in Immunology, Metabolism and Ophthalmology. Financial terms have not been disclosed.
Half-life extension is a critical aspect of developing a successful protein pharmaceutical, as not all efficacious payloads have natural half-lives that are amenable to reasonable dosing intervals or regimens.
The novel PASylation platform is designed to offer improved half-life, pharmacokinetics, pharmacodynamics, bioavailability, solubility and overall enhanced patient compliance and safety. PASylation is a highly tunable technology and offers a paradigm shift in patient care and better compliance in multiple therapeutic areas to improve the quality of life for millions of patients.
"We are pleased to be partnering with XL-protein on the development of new molecules specifically designed to improving the lives of patients, while simultaneously helping to alleviate the clinical burden," said Dr. Rajiv Datar, Chief Executive of DNX. "By combining DNX's 250+ person-years of experience of biologics process development, clinical development and GMP manufacturing expertise with XLp's revolutionary PASylation platform, we hope to 'Make Good Drugs Great,' and to delivering more gain and less pain to patients."
"Working with DNX to create a range of novel long-acting biopharmaceuticals that will provide benefits to patients and to the healthcare services by reducing clinical burden is exciting and satisfying," said Claus Schalper, Managing Director of XL-protein.
Schalper continued, "Our team shares a common passion with DNX to 'Making Good Drugs Even Greater' by contributing our half-life extension / drug delivery technology to support successful product development and commercialization."
Malaria Prevention: New Antibody Targets Unique Binding SiteNews
Scientists have discovered a human antibody that, when tested in mice, prevented malaria infection by binding a specific portion of a surface protein found in almost all strains of the malaria parasite worldwide.READ MORE
Alternative to Antibiotics: Antibody Approach for Treating Multidrug-Resistant Bacterial InfectionsNews
Researchers are developing a promising alternative to antibiotic treatment for infections caused by Klebsiella pneumoniae bacteria resistant to carbapenem antibiotics. The approach uses antibodies to target the K. pneumoniae protective capsule polysaccharide.READ MORE
Domainex Appoints Dr Bodo Spori as Head of Business Development for EuropeNews
Domainex Ltd, a privately-owned drug discovery services company, is pleased to announce the appointment of Dr Bodo Spori as Head of Business Development for Europe.READ MORE
Comments | 0 ADD COMMENT
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018
International Conference on Molecular Biology and Stem Cells
Aug 13 - Aug 15, 2018